CD8A and neoplasm: An analysis of the immune cells in B16-mOVA tumors post-therapy (day 10) showed that our therapeutic approach was as effective as anti-PD-1 therapy (alone or in combination with IMQ) at inducing CD8+ T cells and generating OVA-specific CD8+ T cells in the primary tumor (Extended Data Fig. 10d).